Best results of angioplasty with DES guided by IVUS versus angiography only

Original title: Intravascular Ultrasound-Guided Implantation of Drug-Eluting Stents to Improve Outcome. A Meta-Analysis. Reference: Jae-Sik Jang et al. J Am Coll Cardiol Intv 2014, epub ahead of print.

Several previous studies and meta-analysis showed that implantation of conventional stents (BMS) intravascular ultrasound (IVUS) guided may decrease restenosis and clinical events. This information was not yet clear to drug-eluting stents.

This meta- analysis included 15 studies (3 randomized and 12 observational) with 24849 patients, 11793 received IVUS-guided angioplasty and 13056 guided by angiography. IVUS-guided angioplasty showed a significantly lower rate of death from any cause (OR 0.64, CI 95% 0.51 to 0.81, P < 0.001), acute myocardial infarction (OR 0.57, CI 95% 0.42 to 0.78, P < 0.001) and target vessel revascularization (OR 0.81, CI 95% CI 0.68 to 0.95, P = 0.01). IVUS -guided angioplasty was also associated with significantly less definite or probable thrombosis (OR 0.59, CI 95% 0.42 to 0.82, P = 0.002). Overall, IVUS decreased by 21% the risk of combined events and 36% the risk of death compared with angioplasty guided by angiography alone. In the stratified analysis, according to study design a lower incidence of events in non- randomized studies was observed (OR 0.81; CI 95% 0.68 to 0.96, p = 0.02) compared with randomized studies. In fact the latter only showed a trend in favor of IVUS versus angiography (OR 0.69, CI 95% 0.46 to 1.04, P = 0.07). 

Conclusion

This meta-analysis showed that angioplasty with drug-eluting stents guided by IVUS reduces clinical events compared with angiographic guidance only. Additional trials with adequate statistical power to identify patients or lesions with different risk profiles that may especially benefit from this technique are need it. 

Editorial comment

The advantage of IVUS in this work seems to be related to a lower incidence of heart attack or death rather than decreased angiographic restenosis and repeat revascularization rate. The mechanism is related to the ability of IVUS to identify factors associated with peri-procedural complications such as dissection or hematoma at the edges, sub-expansion or incomplete stent apposition.

SOLACI.ORG

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...

HERA-TAVI: Intra-Annular vs Supra-Annular Valves in TAVI

The HERA-TAVI study is an international multicenter registry that compared the clinical and hemodynamic outcomes of contemporary self-expanding transcatheter heart valves with intra-annular (IA)...